In this free webinar, learn how non-invasive biomarkers are driving a paradigm shift in nonalcoholic steatohepatitis (NASH) clinical trials and clinical care. Attendees will learn how non-invasive tests (NITs) can help overcome the under-diagnosis of NASH. The featured speakers will discuss the challenges and opportunities with using genetic and non-genetic NITs to minimize screen failure rate in clinical development. Attendees will learn about NITs as potential surrogate endpoints that can lead to accelerated/conditional approval. The speakers will discuss emerging NITs for use in both clinical trials and clinical care.
TORONTO, Oct. 12, 2022 /PRNewswire-PRWeb/ -- Diagnosing and assessing the progression of nonalcoholic steatohepatitis (NASH) continue to be some of the most challenging aspects of its management. Most patients would opt out of the diagnostic or follow-up liver biopsy. Also, liver biopsies would not be a front-line test offered by primary care physicians, endocrinologists and diabetologists where a large proportion of undiagnosed patients exist. In addition, recent clinical trial data has shown considerable variability in histopathology readings, making it unreliable for use in clinical trials.
A better approach is needed. Over the last 10 years, there has been increasing interest in the development and validation of non-invasive tests (NITs) that can diagnose NASH, stratify risk, predict clinical outcomes and/or monitor the progression or regression of the disease. NITs may also help to identify NASH sub-phenotypes with potential distinct natural history and prognosis and eventually, facilitate personalized treatment and better response rate. Finally, available data suggest that NITs can predict clinical outcomes and help accelerate clinical development and bring a safe and efficacious therapy to NASH patients with high unmet need.
Currently, many different imaging and blood-based NITs are being explored in clinical trials. In some trials, pre-biopsy enrichment strategies with NITs are becoming increasingly popular to reduce the number of liver biopsy-related screen failures. These NITs include genetic susceptibility alleles, specific protein biomarkers and multi-analyte algorithms. Sorting through these NITs, their use individually and in combination, admittedly requires some navigational assistance.
Register to learn how non-invasive biomarkers are driving a paradigm shift in NASH clinical trials and clinical care.
Join experts from Labcorp Drug Development, Claudia Filozof, MD, PhD, Vice President, Liver Therapeutic Area; Katherine T. Landschulz, PhD, Senior Director, Therapeutic Area Lead, Biomarker Solution Center; Lara Dimick-Santos, MD, Executive Medical Director, CVMER; and Margery A. Connelly, PhD, MBA, FAHA, Strategic Director, Diagnostics R&D, for the live webinar on Thursday, October 27, 2022, at 10:30am EDT (3:30pm BST/UK).
For more information, or to register for this event, visit Time for Change in NASH: How Non-Invasive Biomarkers are Driving a Paradigm Shift in Clinical Trials and Clinical Care.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]
SOURCE Xtalks
Share this article